Logotipo del repositorio
 

The public health benefits and economic value of routine yellow fever vaccination in Colombia.

Vista sencilla de ítem
dc.contributor.authorKieffer, Alexia
dc.contributor.authorHoestlandt, Celine
dc.contributor.authorGil-Rojas, Yaneth
dc.contributor.authorBroban, Anaïs
dc.contributor.authorCastañeda Cardona, Camilo
dc.contributor.authorRosselli, Diego
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística
dc.coverage.spatialAmérica del Surspa
dc.coverage.spatialAmérica Latinaspa
dc.coverage.spatialColombiaspa
dc.date.accessioned2020-03-27T18:26:45Z
dc.date.accessioned2020-04-15T13:26:52Z
dc.date.available2020-03-27T18:26:45Z
dc.date.available2020-04-15T13:26:52Z
dc.date.created2019-05-17
dc.description.abstractenglishObjectives To evaluate the public health benefits and economic value of live-attenuated yellow fever (YF) 17D vaccine in Colombia. Methods A decision tree model was used to assess the theoretical impact of routine YF vaccination of 1-year-olds (no “catch-up”) during the interepidemic period from 1980 to 2002, avoiding capturing the impact of YF vaccine introduction in 2003. The vaccine was assumed to be 99% effective, to provide lifetime protection, and to cover 85% of the target population. Costs per disability-adjusted life-year (DALY) averted were computed from payer and societal perspectives. Univariate sensitivity analyses were performed. Results During the interepidemic period, routine YF vaccination would have averted 2223 nonfatal cases of YF and 65 deaths, leading to an overall reduction of 1365 DALYs. The net cost of this vaccination would have been $25 964 813 (payer’s perspective) and $16 535 465 (societal perspective). Cost per DALY averted was $19 022 and $12 114 from payer and societal perspectives, respectively (all costs in 2015 US dollars). Vaccination was considered cost-effective from both perspectives (ie, between 1- and 3-fold the gross domestic product per capita, $7158) and remains so if price per dose was $2.75 or less and $4.66 from payer and societal perspectives, respectively. Underreporting had the largest impact on the results. Conclusions Routine toddler YF vaccination in Colombia would have been considered cost-effective in the prevaccination era. This study provides insights on the value of vaccination in an upper middle-income country.spa
dc.description.paginas60-65spa
dc.description.quartilescopusQ2spa
dc.description.quartilewosQ2spa
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.format.soportePapel / Electrónicospa
dc.identifierhttps://www-sciencedirect-com.ezproxy.javeriana.edu.co/science/article/pii/S221210991930038Xspa
dc.identifier.doihttps://doi.org/10.1016/j.vhri.2019.01.004spa
dc.identifier.issn2212-1099 / 2212-1102 (Electrónico)spa
dc.identifier.urihttp://hdl.handle.net/10554/47873
dc.languagespaspa
dc.rights.licenceAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceValue in Health Regional Issues; Vol. 20 (2019)spa
dc.subject.keywordColombiaspa
dc.subject.keywordCost-benefit analysisspa
dc.subject.keywordEconomic evaluationspa
dc.subject.keywordVaccinespa
dc.subject.keywordYellow feverspa
dc.subject.keywordYellow fever vaccinespa
dc.titleThe public health benefits and economic value of routine yellow fever vaccination in Colombia.spa
dc.typeinfo:eu-repo/semantics/article
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.localArtículo de revistaspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
1-s2.0-S221210991930038X-main.pdf
Tamaño:
825.13 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.54 KB
Formato:
Plain Text
Descripción:
Descargar

Colecciones

Artículos